Modulari-T
We teach your immune system to attack and cure cancer
Cell and gene therapy promises to one day cure any disease; Modulari-T’s Platform produces the tools to fulfill that promise. Modulari-T has designed a new family of synthetic genes that can reprogram cells to better sense their environment and modify their behavior accordingly. This can be used to engineer immune cells to efficiently recognize and kill cancer cells or to create stem cells able to regenerate any tissue. Modulari-T looks to expand its technology to reach every area of cell therapy and become the platform of reference for cell engineering.
Active Founders
David White
David is the CEO and cofounder of Modulari-T. His expertise spans multiple areas and he is driven by a passion for pushing the boundaries of technology. During his PhD he discovered how protein receptors form complex structures that allow them to alter cells’ behavior. He then took this knowledge and the novel technology that was developed to build Modulari-T. When he’s not thinking up a new way to engineer cells he can be spotted biking or running up a mountain.
Stephanie Mok
Stephanie is a co-founder and COO at Modulari-T. As a PhD graduate from a bioengineering lab, her technical background lies within synthetic biology, advanced 3D cell culture systems, and biomaterials in the context of the cellular microenvironment. She is currently fascinated by the innovations cell-based therapies, food products, and the scale up of their manufacturing. Stephanie gave the unconference talk "Lessons learned and mistakes made growing the world's hottest peppers".
Company Launches
Modulari-T AWAY!
Hi YC, this is @David and @Stephanie from @Modulari-T launching!
WHAT WE DO
Modulari-T is a cell therapy company that can teach your immune system to attack and cure cancer.
We are a dynamic group of scientists bringing together protein engineering, synthetic biology, and immunology to create the world’s most powerful cell programming platform.
By introducing our optimized gene sequences inside immune cells, we can create treatments that are 2x potent as chemotherapy, but that avoids 90% of harmful side-effects.
Today, cell therapy has a high failure rate and is difficult to produce, leaving 20M patients without hope. Modulari-T has the technology to fix this, bring hope to cancer patients, and supercharge the cell therapy market to grow beyond $50B by the end of the decade.
HOW YOU CAN HELP
Connect us with people in the ecosystem! Do you know anyone working in cell therapy or oncology? We want to talk to them, to know about their pain points - academic, biotech/pharma or physicians.
We are hiring! Are you a synthetic biologist or immunologist? Ready to join a new adventure? Become part of the Modulari-T squad (Mod Squad!) in beautiful Montreal!
THE SCIENCE:
We have built a platform to produce a new type of receptor, the Modular Actuation Receptor Complex or MARC, that mimics the modular architecture of immune receptors. These receptors can be used to reprogram immune cells to recognize cancer antigens and direct an immune response against tumor cells. Compared to CAR-T cells, MARCs have twice the tumor clearing power and avoid causing immune exhaustion to ensure a long lasting response.
The MARC’s unique architecture allows us to link any extracellular cue with the required signalling outputs across different pathways to achieve therapeutic success.
Oncology is only the first step; the MARC platform is applicable to autoimmunity, neurology, regenerative medicine and more!
HOW WE CAN HELP YOU
Are you a Cell Therapy company? Let us show you how Modulari-T’s MARC platform can help your development. Our platform can do anything but we can’t do everything alone. That’s why we want to partner with you and bring hope to as many patients as we can.
